



Optimapharm announces Jelena Pavlović as Senior Director, Trial Support

Optimapharm, a leading, mid-sized, full-service CRO across Europe and North America, is excited to announce the appointment of Jelena Pavlović as Senior Director, Trial Support, effective August 2023

Jelena Pavlović has joined Optimapharm, bringing over 20 years of experience in global clinical trial operations to lead our Trial Support department within the company.

Jelena is highly experienced in eTMF process development (including Veeva Vault and Medidata RAVE) and their global implementation and integration with other clinical trial management systems, training and line management of global clinical operation teams, site start-up activities, FDA inspections & audits, quality control & compliance. Additionally, she developed a global department of 50+ Project Specialists and led the integration of two different line management teams with diverse backgrounds into a successful Project Specialist management team.

Jelena holds a Master's in Geological Engineering and has finished specialist studies for small and medium enterprises management.

"It is such a great pleasure to join the Optimapharm team! I look forward to meeting new colleagues, facing new challenges and growing together as part of the Optimapharm team. I am very excited for the opportunity to use the experience gained over the past 20 years to develop further the Trial Support department in Optimapharm and help our organization to continue delivering high-quality service to our clients." said Jelena Pavlović, Senior Director, Trial Support.

About Optimapharm

Optimapharm is a leading, mid-sized, full-service CRO across Europe and North America focused on our People, consistent quality delivery to our Clients, and supporting the development of new therapies to improve and save Patients' lives. The company provides successful tailor-made clinical research solutions to Biotech, Pharma, and Medical Device companies in 40 countries.

With 27 strategically located offices, Optimapharm is giving unrivaled access to Patients and Investigators in all countries in Europe and North America, with a total population of over 900 million people. Optimapharm conducts phase I – IV studies in all therapeutic areas, specifically focusing on Oncology/Haemato-oncology, Cardio-metabolic, CNS, Respiratory, GI&GU, Immunology/Rheumatology, and in complex medical device studies. With very strong operational teams, Optimapharm has a reputation for excellence delivery in all projects, including rescue studies.

Optimapharm - We Deliver on Your Promises. Web site: <https://optimapharm.eu/>